Promising CLL combo study halted early – only 8 patients enrolled
NCT ID NCT04230304
First seen Nov 03, 2025 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tested a combination of two drugs, daratumumab and ibrutinib, in people whose chronic lymphocytic leukemia (CLL) had returned or stopped responding to prior treatment. The goal was to see if the combination could shrink or control the cancer better than ibrutinib alone. The trial was terminated early and enrolled only 8 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.